Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
Authors:
- Antonio PalumboAPAntonio Palumbo
- Francesca GayFrancesca Gay
- Patrizia FalcoPFPatrizia Falco
- Claudia CrippaCCClaudia Crippa
- Vittorio MontefuscoVMVittorio Montefusco
- Francesca PatriarcaFPFrancesca Patriarca
- Fausto RossiniFRFausto Rossini
- Simona CaltagironeSCSimona Caltagirone
- Giulia BenevoloGBGiulia Benevolo
- Norbert PescostaNPNorbert Pescosta
- Tommasina GuglielmelliTGTommasina Guglielmelli
- Sara BringhenSBSara Bringhen
- 10 February 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (5) , 800-807
Abstract
Purpose To evaluate the effect of bortezomib as induction therapy before autologous transplantation, followed by lenalidomide as consolidation-maintenance in myeloma patients. Patients and Methods Newly diagnosed patients age 65 to 75 years were eligible. Induction (bortezomib, doxorubicin, and dexamethasone [PAD]) included four 21-day cycles of bortezomib (1.3 mg/m2 on days 1, 4, 8, and 11), pegylated liposomal doxorubicin (30 mg/m2 on day 4), and dexamethasone (40 mg/d; cycle 1: days 1 to 4, 8 to 11, and 15 to 18; cycles 2 to 4: days 1 to 4). Autologous transplantation was tandem melphalan 100 mg/m2 (MEL100) and stem-cell support. Consolidation included four 28-day cycles of lenalidomide (25 mg/d on days 1 to 21 every 28 days) plus prednisone (50 mg every other day), followed by maintenance with lenalidomide (LP-L; 10 mg/d on days 1 to 21) until relapse. Primary end points were safety (incidence of grade 3 to 4 adverse events [AEs]) and efficacy (response rate). Results A total of 102 patients were enro...Keywords
This publication has 34 references indexed in Scilit:
- Thalidomide for treatment of multiple myeloma: 10 years laterBlood, 2008
- Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐upBritish Journal of Haematology, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaNew England Journal of Medicine, 2007
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial.Blood, 2007
- Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to ProgressionJournal of Clinical Oncology, 2007
- Maintenance therapy with thalidomide improves survival in patients with multiple myelomaBlood, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Cancer incidence and mortality in Europe, 2004Annals of Oncology, 2005